Form 4: Black Diamond Therapeutics Director Granted Stock Options Valued at $2.43 Per Share

Ali Behbahani, a Director at Black Diamond Therapeutics, Inc., was granted stock options to purchase 30,550 shares of common stock at an exercise price of $2.43 per share.

Summary

• Ali Behbahani, a Director of Black Diamond Therapeutics, Inc. (BDTX), acquired 30,550 stock options on June 12, 2025.
• The exercise price for these options is $2.43 per share.
• The options will vest in full upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, contingent on Mr. Behbahani's continued service.
• These stock options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Behbahani beneficially owns 30,550 derivative securities (stock options) directly.
• The filing was signed by Zachary Bambach, acting as attorney-in-fact for Ali Behbahani, under a Power of Attorney dated February 29, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a standard equity grant to a director, aligning their interests with shareholders and indicating continued commitment to the company. It is a routine compensation event.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 11, 2035), providing ample time for potential value realization.

Negatives

• No specific negative aspects are identified in this routine insider transaction filing.

Risks

• The value of the stock options is subject to the future performance of Black Diamond Therapeutics' common stock; if the stock price does not rise above the exercise price of $2.43, the options may expire worthless.
• Vesting of the options is contingent on the reporting person's continued service, posing a risk if service is terminated before vesting.

Future Outlook

The document primarily reports a past transaction and does not provide explicit forward-looking statements or guidance regarding the company's future performance, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the biotechnology and pharmaceutical industry, where equity compensation is a standard practice to attract and retain talent, including board members. It reflects a typical compensation structure for directors in publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in corporate governance across various industries, including biotechnology, to align the interests of board members with shareholders.
• The vesting schedule, tied to continued service and a specific date or annual meeting, is a common mechanism to ensure director commitment.
• The exercise price being a specific value ($2.43) indicates it was likely the closing price on the grant date, which is a typical method for setting option prices in line with market value.

Corporate Governance

Related Party Transactions

• The stock option grant to Ali Behbahani, a Director of Black Diamond Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: While not directly impacting all employees, this type of compensation structure for directors can set a precedent for equity-based incentives within the company.
• Director (Ali Behbahani): Receives a significant equity incentive, contingent on continued service and company performance, enhancing personal wealth potential.

Next Steps

• The stock options will vest upon the earlier of June 12, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, SEC Filing, Ali Behbahani